Effectiveness of antiretroviral therapy in individuals who for economic reasons were switched from a once-daily single-tablet regimen to a triple-tablet regimen

To assess the impact on virological outcomes of a switch from branded single-tablet regimen (STR) including tenofovir, efavirenz, and emtricitabine (STR-TEE) to generic triple-tablet regimen (TTR), including tenofovir, efavirenz, and lamivudine (TTR-TEL), which was implemented on April 1, 2011 to ob...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of acquired immune deficiency syndromes (1999) Jg. 66; H. 4; S. 407
Hauptverfasser: Engsig, Frederik N, Gerstoft, Jan, Helleberg, Marie, Nielsen, Lars N, Kronborg, Gitte, Mathiesen, Lars R, Obel, Niels
Format: Journal Article
Sprache:Englisch
Veröffentlicht: United States 01.08.2014
Schlagworte:
Adult
Anti-HIV Agents - administration & dosage
Anti-HIV Agents - economics
Anti-HIV Agents - therapeutic use
CD4 Lymphocyte Count
Denmark - epidemiology
Drug Administration Schedule
Drug Combinations
Female
HIV Infections - drug therapy
HIV Infections - epidemiology
Humans
Male
Middle Aged
Treatment Outcome
Viral Load
Denmark
ISSN:1944-7884, 1944-7884
Online-Zugang:Weitere Angaben
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Abstract To assess the impact on virological outcomes of a switch from branded single-tablet regimen (STR) including tenofovir, efavirenz, and emtricitabine (STR-TEE) to generic triple-tablet regimen (TTR), including tenofovir, efavirenz, and lamivudine (TTR-TEL), which was implemented on April 1, 2011 to obtain economic savings. From the Capital Region of Denmark (covering two-thirds of the Danish HIV patients), we included combination antiretroviral therapy (cART)-naive patients who administered STR-TEE from April 1, 2010 to March 31, 2011 (n = 111) or TTR-TEL from April 1, 2011 to March 31, 2012 (n = 56) and cART-experienced HIV patients who were on STR-TEE from April 1, 2010 (n = 356) or were switched from STR-TEE to TTR-TEL after April 1, 2011 (n = 512). We estimated the fraction with detectable HIV-RNA, development of the 184V/I resistance mutations, and time to switch of cART. Approximately 96.2% of cART-experienced patients on STR-TEE were shifted to TTR-TEL after April 1, 2011. For the naive STR-TEE and TTR-TEL patients, the fractions with detectable HIV-RNA at week 48 were 7.0% and 8.3% and for the cART experienced 4.0% and 4.4%, respectively. The 184V/I resistance mutation was detected in 1 cART-experienced patient on TTR-TEL with virological failure. The risk of switch to a new cART regimen was slightly increased in the cART-experienced population (difference in 1-year risk: 1.5%; 95% confidence interval: -2.4% to 5.4%). In settings comparable with the Danish health care system, the estimated economic savings from a switch from STR-TEE to TTR-TEL can be realized with negligible short-term risk of adverse outcomes.
AbstractList To assess the impact on virological outcomes of a switch from branded single-tablet regimen (STR) including tenofovir, efavirenz, and emtricitabine (STR-TEE) to generic triple-tablet regimen (TTR), including tenofovir, efavirenz, and lamivudine (TTR-TEL), which was implemented on April 1, 2011 to obtain economic savings. From the Capital Region of Denmark (covering two-thirds of the Danish HIV patients), we included combination antiretroviral therapy (cART)-naive patients who administered STR-TEE from April 1, 2010 to March 31, 2011 (n = 111) or TTR-TEL from April 1, 2011 to March 31, 2012 (n = 56) and cART-experienced HIV patients who were on STR-TEE from April 1, 2010 (n = 356) or were switched from STR-TEE to TTR-TEL after April 1, 2011 (n = 512). We estimated the fraction with detectable HIV-RNA, development of the 184V/I resistance mutations, and time to switch of cART. Approximately 96.2% of cART-experienced patients on STR-TEE were shifted to TTR-TEL after April 1, 2011. For the naive STR-TEE and TTR-TEL patients, the fractions with detectable HIV-RNA at week 48 were 7.0% and 8.3% and for the cART experienced 4.0% and 4.4%, respectively. The 184V/I resistance mutation was detected in 1 cART-experienced patient on TTR-TEL with virological failure. The risk of switch to a new cART regimen was slightly increased in the cART-experienced population (difference in 1-year risk: 1.5%; 95% confidence interval: -2.4% to 5.4%). In settings comparable with the Danish health care system, the estimated economic savings from a switch from STR-TEE to TTR-TEL can be realized with negligible short-term risk of adverse outcomes.
To assess the impact on virological outcomes of a switch from branded single-tablet regimen (STR) including tenofovir, efavirenz, and emtricitabine (STR-TEE) to generic triple-tablet regimen (TTR), including tenofovir, efavirenz, and lamivudine (TTR-TEL), which was implemented on April 1, 2011 to obtain economic savings.BACKGROUNDTo assess the impact on virological outcomes of a switch from branded single-tablet regimen (STR) including tenofovir, efavirenz, and emtricitabine (STR-TEE) to generic triple-tablet regimen (TTR), including tenofovir, efavirenz, and lamivudine (TTR-TEL), which was implemented on April 1, 2011 to obtain economic savings.From the Capital Region of Denmark (covering two-thirds of the Danish HIV patients), we included combination antiretroviral therapy (cART)-naive patients who administered STR-TEE from April 1, 2010 to March 31, 2011 (n = 111) or TTR-TEL from April 1, 2011 to March 31, 2012 (n = 56) and cART-experienced HIV patients who were on STR-TEE from April 1, 2010 (n = 356) or were switched from STR-TEE to TTR-TEL after April 1, 2011 (n = 512). We estimated the fraction with detectable HIV-RNA, development of the 184V/I resistance mutations, and time to switch of cART. Approximately 96.2% of cART-experienced patients on STR-TEE were shifted to TTR-TEL after April 1, 2011. For the naive STR-TEE and TTR-TEL patients, the fractions with detectable HIV-RNA at week 48 were 7.0% and 8.3% and for the cART experienced 4.0% and 4.4%, respectively. The 184V/I resistance mutation was detected in 1 cART-experienced patient on TTR-TEL with virological failure. The risk of switch to a new cART regimen was slightly increased in the cART-experienced population (difference in 1-year risk: 1.5%; 95% confidence interval: -2.4% to 5.4%).METHODS AND FINDINGSFrom the Capital Region of Denmark (covering two-thirds of the Danish HIV patients), we included combination antiretroviral therapy (cART)-naive patients who administered STR-TEE from April 1, 2010 to March 31, 2011 (n = 111) or TTR-TEL from April 1, 2011 to March 31, 2012 (n = 56) and cART-experienced HIV patients who were on STR-TEE from April 1, 2010 (n = 356) or were switched from STR-TEE to TTR-TEL after April 1, 2011 (n = 512). We estimated the fraction with detectable HIV-RNA, development of the 184V/I resistance mutations, and time to switch of cART. Approximately 96.2% of cART-experienced patients on STR-TEE were shifted to TTR-TEL after April 1, 2011. For the naive STR-TEE and TTR-TEL patients, the fractions with detectable HIV-RNA at week 48 were 7.0% and 8.3% and for the cART experienced 4.0% and 4.4%, respectively. The 184V/I resistance mutation was detected in 1 cART-experienced patient on TTR-TEL with virological failure. The risk of switch to a new cART regimen was slightly increased in the cART-experienced population (difference in 1-year risk: 1.5%; 95% confidence interval: -2.4% to 5.4%).In settings comparable with the Danish health care system, the estimated economic savings from a switch from STR-TEE to TTR-TEL can be realized with negligible short-term risk of adverse outcomes.CONCLUSIONSIn settings comparable with the Danish health care system, the estimated economic savings from a switch from STR-TEE to TTR-TEL can be realized with negligible short-term risk of adverse outcomes.
Author Helleberg, Marie
Nielsen, Lars N
Kronborg, Gitte
Mathiesen, Lars R
Gerstoft, Jan
Obel, Niels
Engsig, Frederik N
Author_xml – sequence: 1
  givenname: Frederik N
  surname: Engsig
  fullname: Engsig, Frederik N
  organization: Department of Infectious Diseases, Copenhagen University Hospital, Rigshospitalet, Denmark; †Department of Microbiology Diagnostics and Virology, Statens Serum Institut, Copenhagen, Denmark; ‡Department of Infectious Diseases, Copenhagen University Hospital, Nordsjælland Hospital, Denmark; and §Department of Infectious Diseases, Copenhagen University Hospital, Hvidovre, Denmark
– sequence: 2
  givenname: Jan
  surname: Gerstoft
  fullname: Gerstoft, Jan
– sequence: 3
  givenname: Marie
  surname: Helleberg
  fullname: Helleberg, Marie
– sequence: 4
  givenname: Lars N
  surname: Nielsen
  fullname: Nielsen, Lars N
– sequence: 5
  givenname: Gitte
  surname: Kronborg
  fullname: Kronborg, Gitte
– sequence: 6
  givenname: Lars R
  surname: Mathiesen
  fullname: Mathiesen, Lars R
– sequence: 7
  givenname: Niels
  surname: Obel
  fullname: Obel, Niels
BackLink https://www.ncbi.nlm.nih.gov/pubmed/24984188$$D View this record in MEDLINE/PubMed
BookMark eNplkMFKAzEQQINUrK3-gUiOXrYmaba7OZZStVAQQc8lm0zayG5Sk7Slf-OnGrBCwWFgBt6bGZgB6jnvAKE7SkaUiOrxbboYkfOgQlygayo4L6q65r2zvo8GMX5mZcK5uEJ9xkXNaV1fo--5MaCS3YODGLE3WLpkA6Tg9zbIFqcNBLk9Yutyaru3eifbiA8bj40PGJR3vrMKB5DRuwwgAI4Hm9QGNDbBd1hi7xQUWtr2iKN16xaKJJsWUp5a2w4cTj5bKdjtP3SDLk0-CLenOkQfT_P32UuxfH1ezKbLQnFaiULJhjBZGxDMlBVhutKirDSZGFoqIIqoZiwFpQ2YcSM0JyWtM9eMNDxLjA3Rw-_ebfBfO4hp1dmooG2lA7-LK1pyNuGiZFVW70_qrulAr7bBdjIcV39fZT_p54A5
CitedBy_id crossref_primary_10_1093_jac_dkz439
crossref_primary_10_12998_wjcc_v7_i14_1814
crossref_primary_10_1136_bmjopen_2020_046212
crossref_primary_10_1111_hiv_70028
crossref_primary_10_1016_j_therap_2017_10_001
crossref_primary_10_1177_2325958218822304
crossref_primary_10_1177_2050312118816919
crossref_primary_10_1089_aid_2021_0122
crossref_primary_10_1371_journal_pone_0239704
crossref_primary_10_1097_QAD_0000000000000424
crossref_primary_10_1097_QCO_0000000000000106
crossref_primary_10_1002_jia2_25758
crossref_primary_10_1016_j_healthpol_2018_01_002
crossref_primary_10_1097_MD_0000000000001677
crossref_primary_10_1111_hiv_12426
crossref_primary_10_1111_hiv_12701
crossref_primary_10_1007_s40801_016_0070_9
crossref_primary_10_1371_journal_pone_0262533
crossref_primary_10_1177_1078345818792843
crossref_primary_10_1089_apc_2015_0199
crossref_primary_10_1111_bcpt_12585
crossref_primary_10_1111_hiv_12578
ContentType Journal Article
DBID CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1097/QAI.0000000000000199
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Medicine
EISSN 1944-7884
ExternalDocumentID 24984188
Genre Journal Article
GeographicLocations Denmark
GeographicLocations_xml – name: Denmark
GroupedDBID ---
.-D
.XZ
.Z2
01R
0R~
1J1
354
40H
4Q1
4Q2
4Q3
5GY
5RE
5VS
77Y
7O~
8L-
AAAAV
AAAXR
AAGIX
AAHPQ
AAIQE
AAJCS
AAMOA
AARTV
AASOK
AAXQO
ABBUW
ABDIG
ABIVO
ABXVJ
ABZAD
ACCJW
ACDDN
ACEWG
ACGFO
ACGFS
ACIJW
ACILI
ACOAL
ACPRK
ACWDW
ACWRI
ACXNZ
ACZKN
ADGGA
ADHPY
AE3
AE6
AEETU
AFDTB
AFEXH
AFNMH
AFRAH
AFUWQ
AGINI
AHMBA
AHOMT
AHQNM
AHVBC
AIJEX
AINUH
AJCLO
AJIOK
AJNWD
AJZMW
ALKUP
ALMA_UNASSIGNED_HOLDINGS
AMJPA
AMNEI
BKOMP
BOYCO
BQLVK
BYPQX
C45
CGR
CS3
CUY
CVF
DIWNM
DUNZO
E.X
EBS
ECM
EIF
EJD
EX3
F2K
F2L
F2M
F2N
F5P
FCALG
FL-
FRJ
FRP
H0~
HZ~
IKREB
IKYAY
IN~
JK3
JK8
K8S
KD2
KMI
L-C
NPM
N~7
N~B
O9-
OAG
OAH
ODMTH
OHH
OHYEH
OLG
OLH
OLU
OLV
OLY
OLZ
OPUJH
OVD
OVDNE
OVIDH
OVLEI
OWV
OWX
OWY
OWZ
OXXIT
P2P
PQQKQ
RLZ
RXW
S4R
S4S
TAE
TEORI
V2I
VVN
W2D
W3M
WOQ
WOW
X3V
X3W
XYM
YOC
ZZMQN
7X8
ABPXF
ADKSD
ID FETCH-LOGICAL-c4179-cab02a8fe92f5702d7d957d06f15ce0c0cb3a911bef3b9d4051857dd20b406f22
IEDL.DBID 7X8
ISICitedReferencesCount 28
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000339012300015&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 1944-7884
IngestDate Mon Sep 08 12:20:19 EDT 2025
Thu Apr 03 07:05:59 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 4
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c4179-cab02a8fe92f5702d7d957d06f15ce0c0cb3a911bef3b9d4051857dd20b406f22
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMID 24984188
PQID 1542649527
PQPubID 23479
ParticipantIDs proquest_miscellaneous_1542649527
pubmed_primary_24984188
PublicationCentury 2000
PublicationDate 2014-August-1
PublicationDateYYYYMMDD 2014-08-01
PublicationDate_xml – month: 08
  year: 2014
  text: 2014-August-1
  day: 01
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Journal of acquired immune deficiency syndromes (1999)
PublicationTitleAlternate J Acquir Immune Defic Syndr
PublicationYear 2014
SSID ssj0016449
Score 2.2575552
Snippet To assess the impact on virological outcomes of a switch from branded single-tablet regimen (STR) including tenofovir, efavirenz, and emtricitabine (STR-TEE)...
SourceID proquest
pubmed
SourceType Aggregation Database
Index Database
StartPage 407
SubjectTerms Adult
Anti-HIV Agents - administration & dosage
Anti-HIV Agents - economics
Anti-HIV Agents - therapeutic use
CD4 Lymphocyte Count
Denmark - epidemiology
Drug Administration Schedule
Drug Combinations
Female
HIV Infections - drug therapy
HIV Infections - epidemiology
Humans
Male
Middle Aged
Treatment Outcome
Viral Load
Title Effectiveness of antiretroviral therapy in individuals who for economic reasons were switched from a once-daily single-tablet regimen to a triple-tablet regimen
URI https://www.ncbi.nlm.nih.gov/pubmed/24984188
https://www.proquest.com/docview/1542649527
Volume 66
WOSCitedRecordID wos000339012300015&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8RADB58IV58vx9E8DrYdqd25iQiioIuCip7W6bzwMLa6ra6-G_8qSZtV0EQBHvopR0Y0jT5JsmXMHYgQxPYSAnuvRBcxC7hKXp5rmKtnKQe3vWMpYerpNuVvZ66aQNuZVtWObaJtaG2haEY-SG6evTdKo6S4-cXTlOjKLvajtCYZNMdhDKk1UnvO4uAvl7VWWXcBh71xJg6p5LD25PLpnXh-Gq6v_4CMmtnc77w320usvkWZsJJoxdLbMLly2z2uk2kr7CPpmtxa-qg8IASRutXUYRhiCsbXtY7ZDlkX5ytEkaPBSDMBdfymYFq2lFxYeSGDspRRkpggUgroIEokdzqbPAOFJIYOF4RU6sCGgfx5HKoCnyrGlKw_8ejVXZ_fnZ3esHbYQ3c0BAzbnQaRFp6pyIfJ0FkE6vixAZHPoyNC0xg0o5Gy5o630mVRZxIXaisjYIUMYWPojU2lRe522AgrE5Nx3mhZSy0FcrKI-Lj4ulVKh-Gm2x_LPs-_gyU4dC5K17L_rf0N9l68wH7z03Xjj6eM6UIpdz6w-ptNofASDSFfjts2qOE3S6bMW9VVg73ai3De_fm-hMtXN5l
linkProvider ProQuest
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Effectiveness+of+antiretroviral+therapy+in+individuals+who+for+economic+reasons+were+switched+from+a+once-daily+single-tablet+regimen+to+a+triple-tablet+regimen&rft.jtitle=Journal+of+acquired+immune+deficiency+syndromes+%281999%29&rft.au=Engsig%2C+Frederik+N&rft.au=Gerstoft%2C+Jan&rft.au=Helleberg%2C+Marie&rft.au=Nielsen%2C+Lars+N&rft.date=2014-08-01&rft.eissn=1944-7884&rft.volume=66&rft.issue=4&rft.spage=407&rft_id=info:doi/10.1097%2FQAI.0000000000000199&rft_id=info%3Apmid%2F24984188&rft_id=info%3Apmid%2F24984188&rft.externalDocID=24984188
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1944-7884&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1944-7884&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1944-7884&client=summon